A new COVID vaccine had just been approved in the United States and that’s definitely good news for anyone who wishes to get vaccinated as soon as possible. Johnson & Johnson’s vaccine had been approved from emergency use authorization (EUA) on February 27, according to the Food and Drug Administration (FDA).
The good part about the Janssen vaccine is that you only need one dose, compared to the other two vaccines, Pfizer and Moderna, that require two doses. However, a lot of people have been concerned about its efficacy rate. Johnson & Johnson’s vaccine is 72 percent effective in the United States and 66 percent effective when it comes to preventing a mild COVID case, compared to the other two vaccines from Pfizer and Moderna that are 95%, respectively 94% effective.
The Janssen vaccine becomes efficient 28 days after vaccination, and the greatest thing about it is that it has been proven to be 100% effective against COVID-19 hospitalizations and deaths.
While it can be understandable why a lot of people were suspicious about its efficacy, especially when Pfizer and Moderna’s vaccines offer way more protection against COVID-19, we should concentrate more on its ability to prevent severe coronavirus cases and even deaths, explains Nancy M. Bennett, MD, a professor of medicine and public health sciences at the University of Rochester School of Medicine and Dentistry.
RELATED POST: How Effective Is The New Johnson & Johnson Vaccine, According To Experts.
Do you know what characteristics you inherited from your parents? We've all heard that it's impossible for 2 people to…
Have you ever wondered if what you knew about space, or the planets is actually real? Not in the sense…
Were you ever shocked by something you read that seemed a bit too far-fetched to be true but loads of…
As a society, we have been fascinated with everything around us: from nature to the animal kingdom, we have started…
It's been two years since the World Health Organization has named the official start of the Coronavirus Pandemic. And despite…
If you've read any of our articles before, you know that we discussed SARS-CoV-2 many times, due to the fact…